Regulation of bone mass in inflammatory diseases
- PMID: 35120799
- DOI: 10.1016/j.beem.2021.101611
Regulation of bone mass in inflammatory diseases
Abstract
Inflammation is among the major determinants of bone loss in chronic disease and aging. Bone metabolism is radically affected by inflammation with consequent bone loss and increased fracture risk. Various cytokines and mediators are involved in the pathogenesis of bone loss in inflammatory conditions. The present review has the aim of discussing the main pathways involved in the pathogenesis of bone loss in inflammatory diseases, focusing in particular on the Wnt system and its regulators. Literature review of studies published between inception to 2021 on osteoporosis and inflammation was conducted. I will discuss the epidemiology of osteoporosis and fractures in common inflammatory diseases. The molecular basis of bone loss related to inflammation will be discussed as well. Finally, the effects of various anti-inflammatory medications on bone metabolism will be reviewed.
Keywords: bone metabolism; disease modifying drugs; glucocorticoids; inflammation; osteoporosis; wnt system.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Similar articles
-
Inflammatory bowel disease and the risk of osteoporosis and fracture.Maturitas. 2013 Dec;76(4):315-9. doi: 10.1016/j.maturitas.2013.09.009. Epub 2013 Sep 27. Maturitas. 2013. PMID: 24139749 Review.
-
Skeletal morbidity in inflammatory bowel disease.Scand J Gastroenterol Suppl. 2006;(243):59-64. doi: 10.1080/00365520600664276. Scand J Gastroenterol Suppl. 2006. PMID: 16782623 Review.
-
Management of osteoporosis in rheumatoid arthritis patients.Expert Opin Pharmacother. 2015 Mar;16(4):559-71. doi: 10.1517/14656566.2015.997709. Epub 2015 Jan 27. Expert Opin Pharmacother. 2015. PMID: 25626121 Review.
-
Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention.Expert Opin Pharmacother. 2020 Oct;21(14):1725-1737. doi: 10.1080/14656566.2020.1787381. Epub 2020 Jul 1. Expert Opin Pharmacother. 2020. PMID: 32605401 Review.
-
Osteoporosis in inflammatory joint diseases.Osteoporos Int. 2011 Feb;22(2):421-33. doi: 10.1007/s00198-010-1319-x. Epub 2010 Jun 15. Osteoporos Int. 2011. PMID: 20552328 Review.
Cited by
-
Emerging role of liver-bone axis in osteoporosis.J Orthop Translat. 2024 Sep 4;48:217-231. doi: 10.1016/j.jot.2024.07.008. eCollection 2024 Sep. J Orthop Translat. 2024. PMID: 39290849 Free PMC article. Review.
-
Predictive value of serum inflammatory biomarkers in postmenopausal osteoporosis: A cross-sectional study in northwest Iran.Heliyon. 2024 Aug 13;10(17):e36247. doi: 10.1016/j.heliyon.2024.e36247. eCollection 2024 Sep 15. Heliyon. 2024. PMID: 39263180 Free PMC article.
-
Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis.BMC Rheumatol. 2024 Sep 10;8(1):40. doi: 10.1186/s41927-024-00414-6. BMC Rheumatol. 2024. PMID: 39256771 Free PMC article.
-
Association between dietary copper, iron, zinc, selenium intake and osteopenia or osteoporosis in elderly hypertensive patients: a retrospective cohort study.Front Nutr. 2024 Aug 14;11:1419379. doi: 10.3389/fnut.2024.1419379. eCollection 2024. Front Nutr. 2024. PMID: 39206314 Free PMC article.
-
Effects of circulating inflammatory proteins on osteoporosis and fractures: evidence from genetic correlation and Mendelian randomization study.Front Endocrinol (Lausanne). 2024 May 1;15:1386556. doi: 10.3389/fendo.2024.1386556. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38757000 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical